Multiplex assay for comprehensive genotyping of genes involved in drug metabolism, excretion, and transport.
暂无分享,去创建一个
Mark W Farmen | P. Hardenbol | T. Daly | M. Farmen | R. Hockett | S. Close | D. Fu | Dong-Jing Fu | Thomas M Daly | Sandra Close | Paul Hardenbol | Carsten Bruckner | C. Bruckner | X. Miao | Richard D Hockett | Xin Miao | Carmen M Dumaual | Reuben K Njau | Nancy L Bauer | Nancy Watanabe | C. Dumaual | R. Njau | Nancy Watanabe | Nancy L. Bauer
[1] J. de Leon,et al. A Poor Metabolizer for Cytochromes P450 2D6 and 2C19: A Case Report on Antidepressant Treatment , 2006, CNS Spectrums.
[2] H. Ueoka,et al. Polymorphisms of UDP-Glucuronosyltransferase and Pharmacokinetics of Irinotecan , 2002, Therapeutic drug monitoring.
[3] Fuli Yu,et al. Highly multiplexed molecular inversion probe genotyping: over 10,000 targeted SNPs genotyped in a single tube assay. , 2005, Genome research.
[4] P. O'dwyer,et al. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] P. Wedlund. The CYP2C19 Enzyme Polymorphism , 2000, Pharmacology.
[6] M. Ingelman-Sundberg,et al. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. , 1995, The Journal of pharmacology and experimental therapeutics.
[7] Howard L McLeod,et al. Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.
[8] D. Lewis,et al. 57 varieties: the human cytochromes P450. , 2004, Pharmacogenomics.
[9] Kim L R Brouwer,et al. Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[10] D. Lewis,et al. Human P450s in the metabolism of drugs: molecular modelling of enzyme–substrate interactions , 2005, Expert opinion on drug metabolism & toxicology.
[11] A. Mrhar,et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose , 2005, The Pharmacogenomics Journal.
[12] Ronald W. Davis,et al. Multiplexed genotyping with sequence-tagged molecular inversion probes , 2003, Nature Biotechnology.
[13] G. Wilkinson,et al. Drug metabolism and variability among patients in drug response. , 2005, The New England journal of medicine.
[14] Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels , 2009 .
[15] T. Ishizaki,et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. , 2005, Drug metabolism and pharmacokinetics.
[16] D Lindhout,et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. , 1995, The New England journal of medicine.
[17] M. Relling,et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. , 1999, Journal of the National Cancer Institute.
[18] R. Kim,et al. Molecular basis of ethnic differences in drug disposition and response. , 2001, Annual review of pharmacology and toxicology.
[19] P. Hardenbol,et al. Optimal genotype determination in highly multiplexed SNP data , 2006, European Journal of Human Genetics.
[20] J. Brockmöller,et al. Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets , 2005, Pharmacogenetics and genomics.
[21] James Ireland,et al. Optimal genotype determination in highly multiplexed SNP data , 2006, European Journal of Human Genetics.
[22] Ncbi. National Center for Biotechnology Information , 2008 .
[23] D. Lipman,et al. National Center for Biotechnology Information , 2019, Springer Reference Medizin.
[24] R. Kim. Transporters and drug discovery: why, when, and how. , 2006, Molecular pharmaceutics.
[25] M. Eichelbaum,et al. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. , 1991, American journal of human genetics.
[26] M. Olivier. A haplotype map of the human genome , 2003, Nature.
[27] C. Barthélémy,et al. An ADHD 6-year-old child ultrarapid metabolizer for CYP2D6. , 2006, Journal of clinical psychopharmacology.
[28] Shiew-Mei Huang,et al. Scientific perspectives on drug transporters and their role in drug interactions. , 2006, Molecular pharmaceutics.
[29] B. Meshkin,et al. Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. , 2005, Mutation research.
[30] R. Weinshilboum. Inheritance and drug response. , 2003, The New England journal of medicine.